An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vyvgart

Chemical Nameefgartigimod alfa-fcab
Dosage FormInjection (intravenous; (20 mg/mL)
Drug ClassReceptor antagonists
SystemMusculoskeletal
CompanyArgenx
Approval Year2021

Indication

  • For the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Last updated on 2/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyvgart (efgartigimod alfa-fcab) Prescribing Information.2021argenx BV, Zwijnaarde, Belgium
Document TitleYearSource
Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value.2021ICER